162 related articles for article (PubMed ID: 28993364)
1. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Arora N; Gupta A; Sadeghi N
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993364
[TBL] [Abstract][Full Text] [Related]
2. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
[No Abstract] [Full Text] [Related]
3. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
Dittus C; Grover N; Ellsworth S; Tan X; Park SI
Leuk Lymphoma; 2018 Sep; 59(9):2121-2127. PubMed ID: 29303024
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M
Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667
[No Abstract] [Full Text] [Related]
5. [HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy].
Kobayashi H; Miyagi N
Rinsho Ketsueki; 2017; 58(5):443-448. PubMed ID: 28592757
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
7. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Little RF; Pittaluga S; Grant N; Steinberg SM; Kavlick MF; Mitsuya H; Franchini G; Gutierrez M; Raffeld M; Jaffe ES; Shearer G; Yarchoan R; Wilson WH
Blood; 2003 Jun; 101(12):4653-9. PubMed ID: 12609827
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
Koizumi Y; Uehira T; Ota Y; Ogawa Y; Yajima K; Tanuma J; Yotsumoto M; Hagiwara S; Ikegaya S; Watanabe D; Minamiguchi H; Hodohara K; Murotani K; Mikamo H; Wada H; Ajisawa A; Shirasaka T; Nagai H; Kodama Y; Hishima T; Mochizuki M; Katano H; Okada S
Int J Hematol; 2016 Dec; 104(6):669-681. PubMed ID: 27604616
[TBL] [Abstract][Full Text] [Related]
9. [Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
Gui L; He XH; Liu P; Yang JL; Qin Y; Zhou SY; Yang S; Zhang CG; Shi YK
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):762-767. PubMed ID: 27719718
[TBL] [Abstract][Full Text] [Related]
10. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG
Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556
[TBL] [Abstract][Full Text] [Related]
11. Testicular Plasmablastic Lymphoma in an HIV-Negative Patient: A Rare Case Presentation.
Nwanwene K; Khan NAJ; Alsharedi M
J Investig Med High Impact Case Rep; 2021; 9():23247096211017423. PubMed ID: 34032157
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
[TBL] [Abstract][Full Text] [Related]
13. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Castillo JJ; Reagan JL; Sikov WM; Winer ES
Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
[TBL] [Abstract][Full Text] [Related]
15. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
[TBL] [Abstract][Full Text] [Related]
17. An Advanced AIDS Patient With CD4 <20 and Plasmablastic Lymphoma Achieving Complete Response With the V-EPOCH Regimen.
Nelson B; Hong A; Iqbal F; Venkatesan R
Cureus; 2020 Jun; 12(6):e8641. PubMed ID: 32685310
[TBL] [Abstract][Full Text] [Related]
18. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
[TBL] [Abstract][Full Text] [Related]
19. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
20. Plasmablastic lymphoma in HIV patients: Experience at a tertiary care hospital in eastern India.
Bishnu S; Banerjee S; Bandyopadhyay D; Samui S; Bhattacharya S; Bose D
Indian J Cancer; 2015; 52(4):563-7. PubMed ID: 26960478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]